{"commentary":{"count":78,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":37,"podcast":28,"x_thread":13},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04379596\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DG-03","nct_id":"NCT04379596","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dg-03-nct04379596. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DG-03","arms":[{"description":"T-DXd and 5-fluorouracil (5-FU)","label":"Arm 1A","type":"EXPERIMENTAL"},{"description":"T-DXd and capecitabine","label":"Arm 1B","type":"EXPERIMENTAL"},{"description":"T-DXd and durvalumab","label":"Arm 1C","type":"EXPERIMENTAL"},{"description":"T-DXd, capecitabine, and oxaliplatin","label":"Arm 1D(b)","type":"EXPERIMENTAL"},{"description":"T-DXd, 5-FU, and durvalumab","label":"Arm 1E(a)","type":"EXPERIMENTAL"},{"description":"T-DXd, capecitabine, and durvalumab","label":"Arm 1E(b)","type":"EXPERIMENTAL"},{"description":"Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin","label":"Arm 2A","type":"ACTIVE_COMPARATOR"},{"description":"T-DXd monotherapy","label":"Arm 2B","type":"EXPERIMENTAL"},{"description":"T-DXd, 5-FU or capecitabine","label":"Arm 2C","type":"EXPERIMENTAL"},{"description":"T-DXd, pembrolizumab and 5-FU or capecitabine","label":"Arm 2D","type":"EXPERIMENTAL"},{"description":"T-DXd and pembrolizumab","label":"Arm 2E","type":"EXPERIMENTAL"},{"description":"T-DXd, pembrolizumab and 5-FU or capecitabine","label":"Arm 2F","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Arm 3A","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Arm 3B","type":"EXPERIMENTAL"},{"description":"T-DXd, Rilvegostomig and 5-FU or capecitabine","label":"Arm 4A","type":"EXPERIMENTAL"},{"description":"T-DXd, Rilvegostomig and 5-FU or capecitabine","label":"Arm 4B","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Part 5 Main Cohort","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Part 5 Cohort 2","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-05-04","type":"ESTIMATED"},"conditions":["Gastric Cancer"],"enrollment":{"count":452,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Fluorouracil (5-FU)","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"},{"name":"Durvalumab","type":"BIOLOGICAL"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Trastuzumab","type":"BIOLOGICAL"},{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Volrustomig","type":"BIOLOGICAL"},{"name":"Rilvegostomig","type":"BIOLOGICAL"}],"last_update":"2026-08-28","lead_sponsor":"AstraZeneca","official_title":"A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-05-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Ocurrence of dose-limiting toxicities (DLTs)","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Changes from baseline in laboratory parameters","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Changes from baseline in vital signs","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Changes from baseline in electrocardiogram (ECG) results","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)","timeFrame":"(Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months"}],"references":[{"citation":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.","pmid":"40341124","type":"DERIVED"}],"start_date":{"date":"2020-06-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","url":"https://clinicaltrials.gov/study/NCT04379596"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dg-03-nct04379596"}